Table 3.
Comparison of clinical course according to HRCT patterns among patients with SJS-ILD.
| Characteristics | UIP | Probable UIP | Alternative | P value |
|---|---|---|---|---|
| Patient number | 24 | 26 | 12 | |
| Acute exacerbation | 3 (12.5) | 2 (7.7) | 2 (16.7) | 0.675 |
| Pneumonia | 5 (20.8) | 2 (7.7) | 3 (25.0) | 0.092 |
| Pulmonary hypertension | 1 (4.2) | 2 (7.7) | 1 (8.3) | 1.000 |
| ILD progression | 13 (54.2) | 8 (30.8) | 6 (50.0) | 0.249 |
| Pulmonary function testa | ||||
| FVC change, %predicted/year | − 1.81 ± 1.95 | − 0.54 ± 2.01 | − 0.98 ± 2.06 | 0.086 |
| DLCO change, %predicted/year | − 2.27 ± 1.70 | − 1.00 ± 1.22 | − 0.79 ± 1.94 | 0.007 |
| TLC change, %predicted/year | − 0.46 ± 1.57 | 0.28 ± 1.54 | 0.87 ± 2.90 | 0.122 |
Data are presented as mean ± standard deviation or number (%), unless otherwise indicated.
DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, ILD interstitial lung disease, SJS Sjögren syndrome, TLC total lung capacity, UIP usual interstitial pneumonia.
aLung function decline rate was defined as the slope of the linear function estimated using a linear mixed-effects model with random intercept and random slope.